Printer Friendly

APROGENEX, INC. REPORTS THIRD QUARTER LOSS AS EXPECTED

 HOUSTON, Dec. 3 /PRNewswire/ -- Aprogenex, Inc. (AMEX: APG) today announced that it incurred a net loss of $804,000 for the three months ended Sept. 30, 1993, as compared to a net loss of $814,000 for the comparable period of 1992. The current loss was previously disclosed in the Prospectus for the company's initial public offering in October, 1993. Pro forma net loss per common share was $.25 for the three months ended Sept. 30, 1993, vs. $.27 for the comparable period of 1992. The losses for the nine months ended Sept. 30, 1993 and 1992 were $2,207,000 ($.70 per share) and $2,203,000 ($.92 per share), respectively.
 Aprogenex develops and intends to manufacture and market diagnostic test systems based on its proprietary DNA probe technology to identifye? prese nc ?r extent of genetic abnormalities and disease. Using a maternal blood sample, one of the company's products is designed to identify the rare fetal cells circulating within the mother's blood and to permit the diagnosis of up to 95 percent of prenatal genetic abnormalities, such as Down's Syndrome.
 -0- 12/3/93
 /CONTACT: Donald Payne, chief financial officer of Aprogenex, Inc., 713-748-5114/
 (APG)


CO: Aprogenex, Inc. ST: Texas IN: MTC SU: ERN

LD -- NY065 -- 0368 12/03/93 16:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1993
Words:215
Previous Article:AUSTIN UNITES TO SUPPORT APPLE COMPUTER
Next Article:CHOCK FULL O'NUTS SAYS ACCOUNTING REVISIONS WILL NARROW GAIN ON SALE OF HILLSIDE UNIT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters